Preclinical studies of subunit marker vaccine against classical swine fever in terms of safety, antigenic activity and immunogenicity

The purpose of the present study was to evaluate the innocuity, antigenic and immunogenic activity of a subunit marker vaccine against classical swine fever (CSF) prepared from recombinant CSFV protein E2 and containing new generation oil-based adjuvant. The trials conducted demonstrated that the vaccine is innocuous in the animals selected as model and causes no local or systemic adverse reactions following double administration. The preparation’s antigenic activity is high, as it stimulates the production of post-vaccinal antibodies exclusively to the E2 protein of CSVF, which allows distinction between post-vaccination and post-infection immune response. The vaccine ensured the survival of all immunised piglets upon challenge with virulent CSFV, whereas all animals in the control group died.